Generating comparative evidence on new drugs and devices before approval-Reference-Cited by-同舟云学术

Generating comparative evidence on new drugs and devices before approval

Published:2020-03 Issue:10228 Volume:395 Page:986-997
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Naci Huseyin,Salcher-Konrad Maximilian,Kesselheim Aaron S,Wieseler Beate,Rochaix Lise,Redberg Rita F,Salanti Georgia,Jackson Emily,Garner Sarah,Stroup T Scott,Cipriani Andrea

Funder

National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre

Publisher

Elsevier BV

Subject

General Medicine

Reference122 articles.

1. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis;Cipriani;Lancet,2018

2. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials;Naci;Circ Cardiovasc Qual Outcomes,2013

3. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis;Palmer;JAMA,2016

4. Evaluating the impact of the orphan drug act's seven-year market exclusivity period;Sarpatwari;Health Aff (Millwood),2018

5. A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival;Kazandjian;Semin Oncol,2016

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health technology assessments of new specialized therapies: A typology of key challenges and potential policy solutions;Health Policy and Technology;2024-09

2. Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data;The Lancet Psychiatry;2024-02

3. The lack of head-to-head randomised trials and the consequences for patients and national health service: The case of non-small cell lung cancer;European Journal of Clinical Pharmacology;2024-01-20

4. Current philosophical perspectives on drug approval in the real world;Journal of Causal Inference;2024-01-01

5. Muscarinic drug shows efficacy in schizophrenia but much is left to be discovered;The Lancet;2024-01